Search

Bempedoic acid is a novel adenosine triphosphate citrate lyase inhibitor shown to reduce low density lipoprotein cholesterol when used as an adjunct lipid-lowering therapy in patients with high cardiovascular disease (CVD) risk. Our analysis aimed to determine the price at which bempedoic acid would be cost-effective from the Australian health care perspective. A Markov model was designed using data from the Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen (CLEAR) Harmony trial, to model the clinical outcomes and costs of 1000 patients treated with bempedoic acid over a lifetime horizon. Relevant health states were " Alive with CVD," "Alive with recurrent CVD," and " Dead." With annual cycles, patients were at risk of a nonfatal myocardial infarction, coronary revascularization, and death from CVD or non-CVD causes. Costs and utilities were obtained from published sources. Outcomes of interest were the incremental cost-effectiveness ratios in terms of cost per quality-adjusted life year (QALY) gained and cost per year of life saved. Outcomes were discounted at 5% per annum. Among 1000 individuals, bempedoic acid in addition to statin therapy was estimated to save 122 (discounted) years of life and 103 (discounted) QALYs compared with statin therapy alone. At an acquisition cost of AU$584.40 per year (USD$397.01), bempedoic acid would be considered cost-effective within the Australian setting, with an incremental cost-effectiveness ratio of AU$49,890 per QALY gained (USD$33,893) and AU$42,433 per year of life saved (USD$28,827). Bempedoic acid may be cost-effective within the Australian health care setting at an annual acquisition price less than $600. • Bempedoic acid is a novel adjunct lipid-lowering therapy in cardiovascular disease. • CLEAR Harmony demonstrated bempedoic acid reduces low-density lipoprotein. • A Markov model was built to determine the price at which cost-effectiveness occurs. • The Markov model simulated the clinical outcomes and costs over a lifetime. • In Australia, cost-effectiveness is achieved when priced <$600 per person per annum. [ABSTRACT FROM AUTHOR]